GlassScriptPhysician profile
Licette Almonte
NPI 1528229770
$4,076.60
in general payments reported to CMS, 2019-2025
32 companies · $1,416 in 2025
The $1,416 reported for 2025 was more than what 93% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $304 · 2021: $14.86 · 2022: $268 · 2023: $558 · 2024: $808 · 2025: $1,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,681 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,681.15 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $576.64 | 2019-2025 | Veozah, Cresemba, Myrbetriq |
| Sumitomo Pharma America, INC. | $346.51 | 2023-2025 | Myfembree, Gemtesa |
| Abbvie INC. | $328.27 | 2019-2025 | Orilissa, Lo Loestrin Fe, Liletta |
| Sage Therapeutics, LLC | $326.10 | 2024-2025 | Zurzuvae |
| Coopersurgical, INC. | $316.02 | 2019-2025 | Paragard T 380a, Paragard T 380a, Endosee |
| Bayer Healthcare Pharmaceuticals INC. | $296.82 | 2019-2025 | |
| Davol INC. | $193.10 | 2025 | Arista |
| Lupin INC. | $174.60 | 2019-2020 | |
| Therapeuticsmd, INC. | $164.60 | 2019-2022 | |
| Exeltis, USA INC. | $151.59 | 2019-2024 | Slynd |
| Organon LLC | $138.68 | 2023-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $122.88 | 2022-2025 | |
| Evofem Biosciences, INC. | $114.05 | 2024-2025 | Phexxi, Solosec, Phexx |
| Exact Sciences Corporation | $108.50 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $87.00 | 2023-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $85.00 | 2025 | |
| Dexcom, INC. | $80.78 | 2025 | Dexcom G6 Transmitter |
| Supernus Pharmaceuticals, INC. | $69.37 | 2025 | Qelbree |
| Vertical Pharmaceuticals, LLC | $67.77 | 2019 | |
| Mylan Pharmaceuticals INC. | $55.37 | 2019-2020 | |
| Hologic Sales and Service, LLC | $54.16 | 2024 | Aptima |
| Allergan, INC. | $38.41 | 2019 | |
| Mission Pharmacal Company | $24.98 | 2019 | |
| Medtronic, INC. | $23.84 | 2023 | Truclear |
| Millicent US INC | $19.93 | 2025 | Intrarosa, Femlyv |
| Roche Diagnostics Corporation | $18.31 | 2019 | |
| Ibsa Pharma INC. | $17.80 | 2023 | Tirosint, Licart |
| Vertex Pharmaceuticals Incorporated | $17.73 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.64 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.92 | 2019 | |
| Merck Sharp & Dohme LLC | $14.32 | 2019 | |
| Avion Pharmaceuticals | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Licette Almonte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.